Company · founded 2003

Mapp Biopharmaceutical (United States)

San Diego, United States · mappbio.com

Manage this page

Citations, last 5 years: 430
Works, last 5 years: 32
h-index: 90
Scientists listed: 5
Grants since 2016: 15

Grants received

2025–2027 · research · R44

A Novel Cost-Effective Multispecific Therapeutic for Dengue

Nathan Beutler · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$294.6k

2025–2028 · grant · SB1

Development of highly potent human monoclonal for RSV immunoprophylaxis

Ellen Monson · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$993.4k

2018–2023 · research · R44

Development of highly potent human monoclonal for RSV immuno-prophylaxis

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$801kRespiratory viral infections research

2018–2020 · research · R44

Post-exposure immunotherapy for ricin exposure

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$298kToxin Mechanisms and Immunotoxins

2018–2020 · research · R43

Development of highly potent human monoclonals for RSV immunoprophylaxis

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$300kRespiratory viral infections research

2018–2023 · research · R44

Development of highly potent human monoclonal for RSV immuno-prophylaxis

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$998.8kRespiratory viral infections research

2018–2023 · research · R44

Development of highly potent human monoclonal for RSV immuno-prophylaxis

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$947.9kRespiratory viral infections research

2018–2019 · research · R43

Development of highly potent human monoclonals for RSV immunoprophylaxis

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$300kRespiratory viral infections research

2017–2018 · research · R43

Direct Sequencing of Antibodies of the Influenza Immune Response

Adrian Guthals · Mapp Biopharmaceutical (United States) · funded by Centers for Disease Control and Prevention

$225k

2017–2018 · research · R43

Direct sequencing of serum antibodies after infection

Adrian Guthals · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$255kViral Infections and Outbreaks Research

2016–2017 · research · R43

Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$240.2k

2014–2020 · research · R01

An Immunoprotectant for Argentine Hemorrhagic Fever

Larry Zeitlin · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$1MViral Infections and Outbreaks Research

2009–2020 · grant · SB1

MR191_ An Immunoprotectant for Marburg Virus

Ronald T Aimes · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$1MViral Infections and Outbreaks Research

2009–2021 · grant · SB1

MR191_ An Immunoprotectant for Marburg Virus

Ronald T Aimes · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$1MViral Infections and Outbreaks Research

2009–2020 · grant · SB1

MR191_ An Immunoprotectant for Marburg Virus

Ronald T Aimes · Mapp Biopharmaceutical (United States) · funded by National Institutes of Health

$1MViral Infections and Outbreaks Research